Jiangyuan Liu

Jiangyuan Liu

Auto-generated profile, based on publicly available information

Jiangyuan Liu

The First College of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, 310053, Zhejiang, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2025 in Phytomedicine
Verified
Journal Article
Closed access
XWXuan Wan
Xuan Wan
PXPengchao Xu
Pengchao Xu
XZXing Zhou
Xing Zhou
JLJiangyuan Liu
Jiangyuan Liu
YYYiwen Yang
Yiwen Yang
HXHanting Xia
Hanting Xia

2 July 2025 in Journal of Orthopaedic Translation
Verified
Journal Article
Open access
XZXuefei Zhao
Xuefei Zhao
HXHanting Xia
Hanting Xia
YYYiwen Yang
Yiwen Yang
TMTianyou Ma
Tianyou Ma
YLYichen Lu
Yichen Lu
HJHongting Jin
Hongting Jin
Cartilage defects (CDs) present a significant challenge in orthopaedic medicine. Owing to the inherently limited regenerative capacity of cartilaginous tissue, defects usually do not heal via natural repair processes. Consequently, damaged tissue is replaced by fibrocartilage-like tissues instead of the original hyaline cartilage. Therefore, inhibiting fibrocartilage formation while promoting hyalinisation may represent a novel strategy for CD therapy. Although studies have explored the role of interleukin (IL)-17A and ferroptosis in the fibrosis of visceral organs, such as the liver, lungs, and kidneys, their implication in cartilage fibrosis and fibrocartilage formation remains unclear. Herein, we aimed to determine whether IL-17A and ferroptosis are collectively involved in the process of cartilage fibrosis and to investigate the effects of amygdalin (AMD) and magnesium ions (Mg2+) in cartilage regeneration and the potential molecular mechanisms underlying these effects. Cartilage samples were collected from patients with osteoarthritis and subjected to immunohistochemistry analysis to assess fibrocartilage formation indicators within the degenerated areas. Quantitative real-time polymerase chain reaction, western blot, and immunohistochemistry analyses were employed to assess changes in cartilage anabolism and expression of fibrocartilage markers after treatment with different concentrations of AMD. We also treated chondrocytes with an IL-17A/RA antagonist, a ferroptosis inhibitor, a ferroptosis inducer, and AMD, and measured the changes in fibrocartilage-, ferroptosis-, and IL-17 signalling-associated factors. Finally, mice with microfracture (MF)-induced CDs were administered intra-articular injections of either saline, AMD (10 μmol/L), MgCl2 (0.5 mmol/L), or AMD (10 μmol/mL) plus MgCl2 (0.5 mmol/L) twice a week. After 4 and 8 weeks, chondral repair was assessed through histological and immunohistochemical analyses in each group. IL-17A activated lipid peroxidation, leading to chondrocyte ferroptosis, while AMD suppressed IL-17 signalling, thereby mitigating the decrease in glutathione peroxidase 4 (GPX4) expression induced by IL-17A or erastin. In mice with MF surgery-induced CD, the combination of AMD and Mg2+ mitigated oxidative stress, thereby enhancing the positive effects of Mg2+. This combination led to a significant improvement in chondrogenesis, activation of anabolic processes, and reduction of catabolic activity in the articular cartilage, ultimately supporting cartilage repair and regeneration. AMD targets IL-17 signalling to inhibit chondrocyte ferroptosis. Furthermore, the combination of AMD and Mg2+ suppresses IL-17A/GPX4 signalling, suppressing fibrocartilage formation and fostering hyaline cartilage regeneration. In the present study, we showed that IL-17A may represent a promising therapeutic target for cartilage repair and regeneration. A conservative therapeutic strategy involving joint injections of AMD (a natural plant extract) and Mg2+ (a crucial endogenous factor that promotes chondrogenesis) facilitated effective cartilage repair and regeneration. This strategy represents a cost-effective approach with potential for clinical application.

20 June 2022 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
YLYunfeng Luo
Yunfeng Luo
HXHanting Xia
Hanting Xia
JWJiacai Wang
Jiacai Wang
QHQian Hu
Qian Hu
YLYinghua Luo
Yinghua Luo
FYFengyun Yang
Fengyun Yang
Background. The Jiawei Yanghe decoction (JWYHD) is a traditional Chinese medicine formula for the treatment of osteoporosis, but its therapeutic mechanism has not been fully elucidated, and the therapeutic target of the intervention disease needs to be further verified. The dysfunction of bone mesenchymal stem cells (BMSCs) is considered to be an important pathogenesis of postmenopausal osteoporosis (PMOP). The purpose of this study was to explore how JWYHD regulates BMSC differentiation through the BMP-SMAD signal pathway. Methods. In the in vivo study, we used an ovariectomized PMOP rat (n=36, 2-month-old, 200±20g) model and femur micro-CT analysis to study the effect of JWYHD on bone loss in rats. By immunofluorescence, the translocation expression of BMP2, a key protein in the pathway, was detected. Serum bone metabolism was detected by an enzyme-linked immunosorbent assay (ELISA). Alkaline phosphatase (ALP) activity was detected by alkaline phosphatase staining (ALPS), osteogenesis and matrix mineralization were detected by alizarin red staining (ARS), the adipogenic ability of BMSCs was detected by oil red staining (ORS), and CFU is used to detect the ability of cells to form colonies. The expression of related proteins was detected by western blotting. Results. In vivo and in vitro, the OP phenotypes of SD rats induced by ovariectomy (OVX) included impaired bone mineral density and microstructure, abnormal bone metabolism, and impaired MSC differentiation potential. JWYHD treatment reversed this trend and restored the differentiation potential of MSCs. JWYHD medicated serum and direct intervention of drugs activated the BMP-SMAD signaling pathway, promoted the osteogenic differentiation of BMSCs, and inhibited their adipogenic differentiation. Conclusions. Our data identified that JWYHD is an effective alternative drug for the treatment of PMOP that functions to stimulate the differentiation of BMSCs into osteoblasts in the BMP-SMAD signaling-dependent mechanism.

22 July 2026 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
JLJiangyuan Liu
Jiangyuan Liu
KCKairui Chen
Kairui Chen
JWJingyuan Wen
Jingyuan Wen
QZQinghe Zeng
Qinghe Zeng
LCLiangyan Cheng
Liangyan Cheng
YWYungang Wu
Yungang Wu
Osteoporosis (OP) is a prevalent skeletal disorder characterized by progressive bone mass loss and deteriorated microarchitecture, in which oxidative stress‐induced mesenchymal stem cell (MSC) dysfunction serves as a core pathogenic mechanism. Yougui Pills (YGPs), a classical traditional Chinese medicine formula, are widely applied in clinical OP management, yet the cellular and molecular mechanisms underlying their anti‐osteoporotic effects remain incompletely defined. This study aimed to elucidate the bone‐protective role of YGPs in OP and explore the underlying mechanism, focusing on oxidative stress modulation in MSCs and the Nrf2/HO‐1 signalling pathway. The bioactive components of YGPs and YGP‐containing serum were characterized via UPLC. In vivo, an ovariectomy (OVX) mouse model was established to evaluate YGPs' effects on bone mass, trabecular microstructure and osteogenesis using micro‐CT, histological and immunohistochemical assays; public GEO datasets were re‐analysed to profile transcriptomic alterations and oxidative stress signatures in OP‐derived MSCs. In vitro, H 2 O 2 was used to induce ROS accumulation and oxidative injury in MSCs, with assessments of cell proliferation, apoptosis, ROS levels, migration and osteogenic differentiation. Network pharmacology and siRNA‐mediated gene silencing were conducted for target prediction and mechanistic validation. In vivo results showed that YGP treatment significantly ameliorated OVX‐induced osteopenia, increased bone mineral density, improved trabecular microstructure, and upregulated osteogenic markers (ALP, OCN, Runx2, COL1A1). Transcriptomic re‐analysis revealed upregulated oxidative stress markers in OP MSCs, consistent with In vitro findings that YGPs attenuated H 2 O 2 ‐triggered ROS overproduction, suppressed apoptosis and ectopic lipid deposition, and enhanced MSC proliferation, migration and osteogenic differentiation. Mechanistically, YGPs activated the Nrf2/HO‐1 signalling axis, while Nrf2 knockdown abrogated YGPs' cytoprotective and pro‐osteogenic effects. In conclusion, YGPs mitigate oxidative stress‐induced MSC dysfunction and promote osteogenesis via the Nrf2/HO‐1 pathway, supporting YGPs as a promising therapeutic candidate for OP.